Novembre 2021 - Nouscom

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion

Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]

Nouscom to present interim data from Phase 1 trial evaluating NOUS-209, an ‘off-the-shelf’ neoantigen cancer vaccine for the treatment of MSI-H solid tumors

Results presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting BASEL, Switzerland – 10th November 2021 – Nouscom, a clinical stage immuno-oncology company developing [...]

Nouscom AG: Abstract on interim results from Phase 1 trial for NOUS-209, an “off-the-shelf” neoantigen cancer vaccine, in MSI-H solid tumors will be presented at SITC

Our abstract “Phase 1 Interim Study Results of Nous-209, an Off-the-Shelf Immunotherapy, with Pembrolizumab, for the Treatment of Tumors with a Deficiency in Mismatch Repair/ Microsatellite [...]